



Amendment of Terms of Convertible Notes

NEW YORK and SYDNEY, Australia, May 18, 2022 - Beroni Group (OTCQX: BNIGF; NSX: BTG) ("Beroni" or the "Company"), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that the maturity date of the 20,736 convertible notes issued in May 2020, which was extended to May 2022 in November 2021, has been amended to the date of Official Listing of the Company on the Nasdaq Stock Market. In addition, the mandatory redemption clause of the convertible notes was amended to one of mandatory conversion such that on the maturity date, the Company must convert all convertible notes held by the investor that have not otherwise been converted or redeemed. Beroni is in the process of applying for a listing on NASDAQ and there is not a firm listing date on NASDAQ at this stage. The Company will keep shareholders informed of the listing process.

For details of the convertible notes, please refer to our announcement dated 27 May 2020.

-###-

About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of FDA/CE approved virus diagnostic kits, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA. To learn more about Beroni, please visit www.beronigroup.com.

For further information, please contact us at:

Phone: +61 2 9159 1827

Email: enquiry@beronigroup.com

Website: www.beronigroup.com